Publicacións en colaboración con investigadores/as de Universidad de Sevilla (27)

2024

  1. Efficacy of Tamoxifen Metabolites in Combination with Colistin and Tigecycline in Experimental Murine Models of Escherichia coli and Acinetobacter baumannii

    Antibiotics, Vol. 13, Núm. 5

2023

  1. Role of blaTEM and OmpC in the piperacillin-tazobactam resistance evolution by E. coli in patients with complicated intra-abdominal infection

    Journal of Infection, Vol. 87, Núm. 3, pp. 220-229

2021

  1. AOA-2 Derivatives as Outer Membrane Protein A Inhibitors for Treatment of Gram-Negative Bacilli Infections

    Frontiers in Microbiology, Vol. 12

  2. Efficacy of lysophosphatidylcholine as direct treatment in combination with colistin against acinetobacter baumannii in murine severe infections models

    Antibiotics, Vol. 10, Núm. 2, pp. 1-8

  3. Impact of the COVID-19 Pandemic on Survival in the Patients With the Intra-Abdominal Infections

    Frontiers in Medicine, Vol. 8

  4. Potential tamoxifen repurposing to combat infections by multidrug-resistant gram-negative Bacilli

    Pharmaceuticals, Vol. 14, Núm. 6

  5. Repurposing of the tamoxifen metabolites to combat infections by multidrug-resistant gram-negative bacilli

    Antibiotics, Vol. 10, Núm. 3

  6. Repurposing of the tamoxifen metabolites to treat methicillin-resistant staphylococcus epidermidis and vancomycin-resistant enterococcus faecalis infections

    Microbiology Spectrum, Vol. 9, Núm. 2

  7. Semirapid detection of piperacillin/tazobactam resistance and extended-spectrum resistance to b-lactams/b-lactamase inhibitors in clinical isolates of escherichia coli

    Microbiology Spectrum, Vol. 9, Núm. 2

2020

  1. Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: Study protocol for the prospective multicentre OptimBioma study

    BMJ Open, Vol. 10, Núm. 7

  2. Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 1, pp. 77-85

  3. Repositioning rafoxanide to treat Gram-negative bacilli infections

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 7, pp. 1895-1905

  4. Role of PstS in the pathogenesis of acinetobacter baumannii under microaerobiosis and normoxia

    Journal of Infectious Diseases, Vol. 222, Núm. 7, pp. 1204-1212

2019

  1. Drug repurposing for the treatment of bacterial and fungal infections

    Frontiers in Microbiology, Vol. 10, Núm. JAN

  2. Phylogeny, resistome, and virulome of escherichia coli causing biliary tract infections

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  3. Prevalence and clinical impact of Streptococcus pneumoniae nasopharyngeal carriage in solid organ transplant recipients

    BMC Infectious Diseases, Vol. 19, Núm. 1

  4. The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli

    International Journal of Antimicrobial Agents, Vol. 54, Núm. 4, pp. 507-512

2018

  1. Efficacy of colistin and its combination with rifampin in Vitro and in experimental models of infection caused by carbapenemase-producing clinical isolates of Klebsiella pneumoniae

    Frontiers in Microbiology, Vol. 9, Núm. MAY

  2. Heteroresistance to piperacillin-tazobactam in clinical isolates of Escherichia coli sequence type 131

    Antimicrobial Agents and Chemotherapy

  3. In vitro Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and/or Colistin-Resistant Enterobacteriaceae

    Frontiers in Cellular and Infection Microbiology, Vol. 8